Cargando…
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
BACKGROUND: Although management guidelines exist for several genes associated with a 2‐fold to 5‐fold increase in the relative risk for certain cancers, the value of testing for them remains controversial. METHODS: De‐identified personal and family history data for 654 individuals with pathogenic va...
Autores principales: | Vysotskaia, Valentina, Kaseniit, K. Eerik, Bucheit, Leslie, Ready, Kaylene, Price, Kristin, Johansen Taber, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003834/ https://www.ncbi.nlm.nih.gov/pubmed/31682005 http://dx.doi.org/10.1002/cncr.32572 |
Ejemplares similares
-
UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2
por: Hanson, Helen, et al.
Publicado: (2023) -
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
por: Cummings, Shelly, et al.
Publicado: (2021) -
Enhancement of the RAD51 Recombinase Activity by the Tumor Suppressor PALB2
por: Dray, Eloïse, et al.
Publicado: (2010) -
Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021) -
Roles of XRCC2, RAD51B and RAD51D in RAD51-Independent SSA Recombination
por: Serra, Heïdi, et al.
Publicado: (2013)